A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology

NCT07481019 | Not Yet Recruiting

• 1 other identifier: 2023/00698
• Study Type: interventional
• Target: 250
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to evaluate whether an electronic patient-reported outcome measure (ePROM)-guided flexible scheduling system can improve outpatient clinic resource utilisation in patients attending dermatology outpatient clinics for routine follow-up. The main questions it aims to answer are:

• Does the intervention reduce the number of actualised outpatient visits over 12 months compared with standard fixed scheduling?
• Does the intervention group achieve higher adherence to monthly ePROM monitoring, as measured by the proportion of completed ePROM submissions?

Conditions

Chronic Dermatological Conditions; Eczema; Urticaria; Psoriasis; Acne

Keywords

dermatology; flexible scheduling; patient initiated follow up; electronic patient-reported outcomes; ePROMs; Bayesian decision support; outpatient care; health services research; randomised controlled trial; implementation science; healthcare utilisation; appointment no-shows; value-based care

Outcome Measures

Primary Outcomes (2)

• Number of actualised outpatient visits

  Difference in actualised outpatient visits (in-person + teleconsult) over 12 months (effectiveness outcome).

  baseline to week 52

• Proportion of completed monthly ePROMs

  Difference in proportion of completed monthly ePROMs (implementation outcome)

  baseline to week 52

Secondary Outcomes (10)

• No-show rate

  baseline to week 52

• Cancelled or rescheduled appointments

  baseline to week 52

• Urgent care or unscheduled visits

  baseline to week 52

• Skin-specific Quality of Life Impairment

  baseline, 6 months, 12 months

• Clinician-assessed disease severity

  baseline to week 52

Study Arms (2)

Intervention Arm

EXPERIMENTAL

Participants in the intervention arm will not receive routine follow-up appointments at the end of their consultation. Instead, their monthly ePROM responses will feed a two-layer Bayesian decision system to determine appointment need.

Behavioral: Flexible ePROM-guided Scheduling System; Behavioral: electronic patient reported outcome measures (ePROMs)

Control Arm

ACTIVE COMPARATOR

Participants in the control arm will continue standard care, with follow-up appointments scheduled at the end of each consultation. The ePROM responses may be used by patients for self-tracking and will be available to clinicians to inform decision-making at subsequent visits.

Behavioral: electronic patient reported outcome measures (ePROMs)

Interventions

electronic patient reported outcome measures (ePROMs) BEHAVIORAL

Monthly electronic patient reported outcome measures (ePROMs) surveys will be sent to patients' mobile devices to capture self-reported disease severity data.

Control Arm; Intervention Arm

Flexible ePROM-guided Scheduling System BEHAVIORAL

Monthly ePROM responses will feed a Bayesian decision system to determine appointment need, which will then be used to make recommendations to patients for scheduling of appointments.

Intervention Arm

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Dermatology outpatients otherwise due for a follow-up appointment within six months.
• Ability to independently navigate and complete ePROMs.
• Ability to provide informed consent (including parental consent for minors).

You may not qualify if:

• Patients who require fixed or scheduled in-person visits, including those needing skin cancer surveillance, bedside procedures (e.g., liquid nitrogen therapy), surgical interventions, or routine blood tests for immunosuppressive therapy.

Sponsors & Collaborators

• National University Hospital, Singapore: lead

MeSH Terms

Conditions

Eczema; Urticaria; Psoriasis; Acne Vulgaris

Condition Hierarchy (Ancestors)

Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Skin Diseases, Vascular; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Skin Diseases, Papulosquamous; Acneiform Eruptions; Sebaceous Gland Diseases

Study Officials

• Ellie Choi, MBBS

  National University Hospital, Singapore

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ellie Choi, MBBS

CONTACT

65 6908 2222; dermatology@nuhs.edu.sg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 15, 2026
• First Posted: March 18, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): June 1, 2029
• Study Completion (Estimated): December 1, 2029
• Last Updated: July 1, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF, ANALYTIC CODE
• Time Frame: IPD and supporting information will be available from the time of publication and for four years thereafter.
• Access Criteria: IPD and supporting information will be available from the study team on a case-by-case basis upon request.